热门资讯> 正文
Iterum Therapeutics非GAAP每股收益为-0.13美元
2025-08-05 19:16
- Iterum Therapeutics plc(ITRM) 0
- Cambria Global Asset Allocation ETF(GAA) 0
- WisdomTree Earnings 500 Fund(EPS) 0
- Iterum Therapeutics press release (NASDAQ:ITRM): Q2 Non-GAAP EPS of -$0.13.
- Cash and cash equivalents were $13.0 million as of June 30, 2025. Based on Iterum’s current operating plan, Iterum expects that its cash and cash equivalents as of June 30, 2025, together with $2.2 million of net proceeds raised under its at-the-market offering program from July 1, 2025 through August 1, 2025, will be sufficient to fund its operations into 2026. The foregoing estimate gives effect to Iterum’s currently planned commercial launch of ORLYNVAHTM in August 2025. As of August 1, 2025, Iterum had approximately 44.7 million ordinary shares outstanding.
More on Iterum Therapeutics
- Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
- Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026
- Iterum Therapeutics Non-GAAP EPS of -$0.10
- Seeking Alpha’s Quant Rating on Iterum Therapeutics
- Historical earnings data for Iterum Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
